問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
林彥廷
下載
2025-05-01 - 2030-12-01
Condition/Disease
• PFS is defined as the time elapsed from randomization to disease progression or death from any cause (whichever occurs first). Disease progression is assessed by the trial administrator according to RECIST v1.1.
Test Drug
Docetaxel AqVida 20 mg/ml concentrate for solution for infusion RMC-6236
Participate Sites5Sites
Recruiting5Sites
2025-05-01 - 2030-04-30
ORR is defined as the percentage of participants who achieve a complete response (CR) or a partial response (PR) as assessed by BICR according to RECIST v1.1. OS is defined as the length of time elapsed from random assignment until the date of death from any cause.
TRODELVY for Injection
Participate Sites9Sites
Recruiting9Sites
2025-08-01 - 2031-12-31
Participate Sites7Sites
Recruiting7Sites
2018-12-01 - 2027-12-31
Participate Sites4Sites
Recruiting4Sites
Division of Hematology & Oncology
2020-01-01 - 2026-12-31
2024-01-01 - 2040-12-31
2020-02-01 - 2025-12-10
Participate Sites8Sites
Terminated3Sites
2020-10-01 - 2026-01-08
Participate Sites3Sites
Not yet recruiting1Sites
Recruiting2Sites
2020-07-01 - 2022-05-01
Participate Sites2Sites
2022-01-01 - 2025-12-31
Participate Sites1Sites
Recruiting1Sites
全部
